Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial - 09/01/20
Abstract |
Background |
Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects.
Objective |
To assess the safety and efficacy of crisaborole 2% ointment—a nonsteroidal phosphodiesterase 4 inhibitor—in the treatment of intertriginous, anogenital, and facial psoriasis.
Methods |
A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS).
Results |
After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events.
Limitations |
The study was limited to a single tertiary care center and small sample size.
Conclusion |
Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : crisaborole, facial psoriasis, genital psoriasis, intertriginous psoriasis, inverse psoriasis, PDE-4 inhibitor
Abbreviations used : IL, PDE-4, TLSS
Plan
Funding sources: Supported by a Pfizer ASPIRE Dermatology Research Award. |
|
Conflicts of interest: Dr Lebwohl received honoraria serving as a consultant for Allergan, Aqua, Arcutis Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, Menlo Therapeutics, Mitsubishi Pharma/Neuroderm LTD, Promious/Dr. Reddy, Theravance Biopharma, and Verrica Pharmaceuticals Inc; received grants and/or research funding serving as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Incyte Corporation, Janssen Research and Development,LLC/Johnson & Johnson, Kadmon Corporation LLC, Leo Pharma, MedImmune/AstraZeneca, Novartis Pharmaceuticals Corp, Ortho-Dermatologics, Pfizer, SCIDerm, UCB, and ViDac Pharma; and received honoraria serving in another role for Corrona Inc, Facilitation of International Dermatology Education, and the Foundation for Research and Education in Dermatology. All other authors (Dr Hashim, Dr Chima, Dr Kim, Dr Bares, Mr Yao, Ms Singer, Mr Chen, Mr Genece, Ms Baum, Dr Kimmel, Dr Nia, and Mr Gagliotti) have no conflicts to disclose. |
Vol 82 - N° 2
P. 360-365 - février 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?